Resistant Hypertension: Drug Development Pipeline Study, H1 2018
Resistant Hypertension pipeline comprises of 7 drugs under development as of March 2018. Of these, 1 drug is in Phase 1 and 3 drugs in phase 2. Further, 3 drugs are in Pre clinical stage.
10 companies are developing the pipeline for Resistant Hypertension. Of this, Idorsia Pharmaceuticals Ltd’s therapeutic candidate is likely to advance into Phase 3 in H1-2018.
Resistant hypertension is one of the potential causes for cardiovascular disease. The condition involves the patient to witness sustained high blood pressures. Despite administration of three or more anti-hypertensive therapies, the targeted pressure of 140/90 (systolic/ diastolic) is not attained.
Around half of the hypertension patients in the US have uncontrolled hypertension, of which around 12% to 15% possess resistant hypertension.
In addition, patients with resistant hypertension typically possess historical diabetes mellitus and chronic kidney condition, resulting in higher complexity.
The most comprehensive pipeline review “Resistant Hypertension- Drug Development Pipeline Study” provides in-depth analysis and update information on Resistant Hypertension pipeline drugs. Current status of all the drugs in the Resistant Hypertension pipeline is provided in the research work.
The report provides detailed analysis of Resistant Hypertension pipeline including companies involved, drugs in different stages of development, drug development details across regions (Region (North America, Europe, Asia Pacific and Rest of the World). Further, the Resistant Hypertension report identifies aspects important in modifying industry market scenarios, increasing opportunities and list of potential companies that impact the Resistant Hypertension industry.
Scope:
10 companies are developing the pipeline for Resistant Hypertension. Of this, Idorsia Pharmaceuticals Ltd’s therapeutic candidate is likely to advance into Phase 3 in H1-2018.
Resistant hypertension is one of the potential causes for cardiovascular disease. The condition involves the patient to witness sustained high blood pressures. Despite administration of three or more anti-hypertensive therapies, the targeted pressure of 140/90 (systolic/ diastolic) is not attained.
Around half of the hypertension patients in the US have uncontrolled hypertension, of which around 12% to 15% possess resistant hypertension.
In addition, patients with resistant hypertension typically possess historical diabetes mellitus and chronic kidney condition, resulting in higher complexity.
The most comprehensive pipeline review “Resistant Hypertension- Drug Development Pipeline Study” provides in-depth analysis and update information on Resistant Hypertension pipeline drugs. Current status of all the drugs in the Resistant Hypertension pipeline is provided in the research work.
The report provides detailed analysis of Resistant Hypertension pipeline including companies involved, drugs in different stages of development, drug development details across regions (Region (North America, Europe, Asia Pacific and Rest of the World). Further, the Resistant Hypertension report identifies aspects important in modifying industry market scenarios, increasing opportunities and list of potential companies that impact the Resistant Hypertension industry.
Scope:
- - All latest industry developments and their impact on projects and companies
- - Complete overview of global Resistant Hypertension therapy options and treatments
- - The pipeline study reviews drug details for Resistant Hypertension by developing companies, institutions, mechanism of action, Target, Route, Phase (pre-clinical/ Discovery, Phase 1, Phase 2, Phase 3, Pre-Registration, IND/ NDA), molecule
- - Mergers, Acquisitions, licensing, co-development and project acquisition news for Resistant Hypertension market
- - Resistant Hypertension drugs being developed in combination with other drugs are also detailed
- - Company wise drugs listed with their current status, partners and news updates
1 TABLE OF CONTENTS
1.1 LIST OF FIGURES
1.2 LIST OF TABLES
2 EXECUTIVE SUMMARY
2.1 DISEASE OVERVIEW
2.2 PIPELINE SNAPSHOT
2.3 PIPELINE DRUGS BY PHASE
2.4 PIPELINE DRUGS BY COMPANY
2.5 PIPELINE DRUGS BY MECHANISM OF ACTION
3 RESISTANT HYPERTENSION- COMPANY WISE PIPELINE ANALYSIS
3.1 BAYER AG PIPELINE, H1 2018
3.2 IDORSIA PHARMACEUTICALS LTD PIPELINE, H1 2018
3.3 IONIS PHARMACEUTICALS, INC PIPELINE, H1 2018
3.4 MARINA BIOTECH INC PIPELINE, H1 2018
3.5 NOVARTIS PHARMACEUTICALS PIPELINE, H1 2018
3.6 SARFEZ PHARMACEUTICALS INC PIPELINE, H1 2018
3.7 ZUMBRO DISCOVERY INC PIPELINE, H1 2018
4 RESISTANT HYPERTENSION DRUG SNAPSHOTS
4.1 IONIS-AGT-LRX Drug Details
4.1.1 Snapshot
4.1.2 Drug Overview-
4.1.3 Mechanism of Action
4.1.4 Current Status-
4.1.5 Trial details
4.2 Aprocitentan Drug Details
4.2.1 Snapshot
4.2.2 Drug Overview
4.2.3 Mechanism of Action
4.2.4 Current Status
4.2.5 Trial details
4.3 LHW090 Drug Details
4.3.1 Snapshot
4.3.2 Drug Overview
4.3.3 Current Status
4.3.4 Mechanism of Action
4.3.5 Trial Details
4.4 SP20203 Drug Details
4.4.1 Snapshot
4.4.2 Drug Overview
4.4.3 Mechanism of Action
4.5 ZD100 Drug Details
4.5.1 Snapshot
4.5.2 Drug Overview
4.5.3 Mechanism of Action
4.5.4 Current Status
4.5.5 Trial details
4.6 IT 103 Drug Details
4.6.1 Snapshot
4.6.2 Drug Overview
4.6.3 Current Status
4.6.4 Trial details
4.7 BAY sGCstim Drug Details
4.7.1 Snapshot
4.7.2 Mechanism of Action
4.7.3 Current Status
5 RECENT DEVELOPMENTS IN RESISTANT HYPERTENSION PIPELINE
5.1 JANSSEN BIOTECH TO PAY $230M IN HYPERTENSION DEAL WITH IDORSIA- December 2017
5.2 MARINA BIOTECH ANNOUNCES AGREEMENT FOR DRUG DEVELOPMENT AND LICENSING WITH AUTOTELIC BIO- JANUARY 2018
5.3 EVALUATION OF CARDIOVASCULAR OUTCOME IN TRH VS NON-TRH- FEBRUARY 2018
6 APPENDIX
6.1 ABOUT VPA RESEARCH
6.2 SOURCES AND RESEARCH METHODOLOGY
1.1 LIST OF FIGURES
1.2 LIST OF TABLES
2 EXECUTIVE SUMMARY
2.1 DISEASE OVERVIEW
2.2 PIPELINE SNAPSHOT
2.3 PIPELINE DRUGS BY PHASE
2.4 PIPELINE DRUGS BY COMPANY
2.5 PIPELINE DRUGS BY MECHANISM OF ACTION
3 RESISTANT HYPERTENSION- COMPANY WISE PIPELINE ANALYSIS
3.1 BAYER AG PIPELINE, H1 2018
3.2 IDORSIA PHARMACEUTICALS LTD PIPELINE, H1 2018
3.3 IONIS PHARMACEUTICALS, INC PIPELINE, H1 2018
3.4 MARINA BIOTECH INC PIPELINE, H1 2018
3.5 NOVARTIS PHARMACEUTICALS PIPELINE, H1 2018
3.6 SARFEZ PHARMACEUTICALS INC PIPELINE, H1 2018
3.7 ZUMBRO DISCOVERY INC PIPELINE, H1 2018
4 RESISTANT HYPERTENSION DRUG SNAPSHOTS
4.1 IONIS-AGT-LRX Drug Details
4.1.1 Snapshot
4.1.2 Drug Overview-
4.1.3 Mechanism of Action
4.1.4 Current Status-
4.1.5 Trial details
4.2 Aprocitentan Drug Details
4.2.1 Snapshot
4.2.2 Drug Overview
4.2.3 Mechanism of Action
4.2.4 Current Status
4.2.5 Trial details
4.3 LHW090 Drug Details
4.3.1 Snapshot
4.3.2 Drug Overview
4.3.3 Current Status
4.3.4 Mechanism of Action
4.3.5 Trial Details
4.4 SP20203 Drug Details
4.4.1 Snapshot
4.4.2 Drug Overview
4.4.3 Mechanism of Action
4.5 ZD100 Drug Details
4.5.1 Snapshot
4.5.2 Drug Overview
4.5.3 Mechanism of Action
4.5.4 Current Status
4.5.5 Trial details
4.6 IT 103 Drug Details
4.6.1 Snapshot
4.6.2 Drug Overview
4.6.3 Current Status
4.6.4 Trial details
4.7 BAY sGCstim Drug Details
4.7.1 Snapshot
4.7.2 Mechanism of Action
4.7.3 Current Status
5 RECENT DEVELOPMENTS IN RESISTANT HYPERTENSION PIPELINE
5.1 JANSSEN BIOTECH TO PAY $230M IN HYPERTENSION DEAL WITH IDORSIA- December 2017
5.2 MARINA BIOTECH ANNOUNCES AGREEMENT FOR DRUG DEVELOPMENT AND LICENSING WITH AUTOTELIC BIO- JANUARY 2018
5.3 EVALUATION OF CARDIOVASCULAR OUTCOME IN TRH VS NON-TRH- FEBRUARY 2018
6 APPENDIX
6.1 ABOUT VPA RESEARCH
6.2 SOURCES AND RESEARCH METHODOLOGY
LIST OF FIGURES
Figure 1: Resistant Hypertension Pipeline by Phase, H1- 2018
Figure 2: Resistant Hypertension Pipeline by Companies, H1- 2018
Figure 3: Company wise Pipeline Drug Phases, H1- 2018
Figure 4: Resistant Hypertension Pipeline by Mechanism of Action, H1- 2018
Figure 5: Mechanism wise Pipeline Drug Phases, H1- 2018
Figure 1: Resistant Hypertension Pipeline by Phase, H1- 2018
Figure 2: Resistant Hypertension Pipeline by Companies, H1- 2018
Figure 3: Company wise Pipeline Drug Phases, H1- 2018
Figure 4: Resistant Hypertension Pipeline by Mechanism of Action, H1- 2018
Figure 5: Mechanism wise Pipeline Drug Phases, H1- 2018
LIST OF TABLES
Table 1: Resistant Hypertension Pipeline by Phase, H1- 2018
Table 2: Resistant Hypertension Pipeline by Companies, H1- 2018
Table 3: Resistant Hypertension Pipeline by Mechanism of Action, H1- 2018
Table 4: Bayer AG - Resistant Hypertension Pipeline, H1- 2018
Table 5: Idorsia Pharmaceuticals Ltd- Resistant Hypertension Pipeline, H1- 2018
Table 6: Ionis Pharmaceuticals, Inc- Resistant Hypertension Pipeline, H1- 2018
Table 7: Marina Biotech Inc- Resistant Hypertension Pipeline, H1- 2018
Table 8: Novartis Pharmaceuticals- Resistant Hypertension Pipeline, H1- 2018
Table 9: Sarfez Pharmaceuticals Inc- Resistant Hypertension Pipeline, H1- 2018
Table 10: Zumbro Discovery Inc- Resistant Hypertension Pipeline, H1- 2018
Table 1: Resistant Hypertension Pipeline by Phase, H1- 2018
Table 2: Resistant Hypertension Pipeline by Companies, H1- 2018
Table 3: Resistant Hypertension Pipeline by Mechanism of Action, H1- 2018
Table 4: Bayer AG - Resistant Hypertension Pipeline, H1- 2018
Table 5: Idorsia Pharmaceuticals Ltd- Resistant Hypertension Pipeline, H1- 2018
Table 6: Ionis Pharmaceuticals, Inc- Resistant Hypertension Pipeline, H1- 2018
Table 7: Marina Biotech Inc- Resistant Hypertension Pipeline, H1- 2018
Table 8: Novartis Pharmaceuticals- Resistant Hypertension Pipeline, H1- 2018
Table 9: Sarfez Pharmaceuticals Inc- Resistant Hypertension Pipeline, H1- 2018
Table 10: Zumbro Discovery Inc- Resistant Hypertension Pipeline, H1- 2018
